Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin plus exenatide added to intensive insulin therapy in obese insulin-resistant type 2 diabetes
2016-003738-25Phase 3Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin plus exenatide, Placebo and Exenatide monotherapy (3 arms). Primary endpoint: Change in HbA1c from baseline to Week 28. Started Oct 2017; status: terminated.
02
Drugs
dapagliflozinexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-003738-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003738-25.